Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical leader focused on pioneering therapies for immuno-inflammatory and dermatologic diseases. This page serves as the definitive source for verified news and press releases related to ACRS's research advancements, strategic partnerships, and operational developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and financial announcements. The curated collection includes updates on novel drug candidates like kinase inhibitors and antibody therapies targeting conditions with significant unmet medical needs.
All content is organized to provide clear insights into ACRS's dual-segment operations – from therapeutic innovations to contract research services. Regular updates ensure stakeholders stay informed about licensing agreements, pipeline expansions, and scientific breakthroughs without promotional bias.
Bookmark this page for streamlined access to essential Aclaris Therapeutics updates. Check back frequently for authoritative reporting on developments impacting both clinical research and investment considerations in the biopharmaceutical sector.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023, at 1:00 PM ET. Members of the management team will engage in a fireside chat, which can be accessed via the 'Events' page on Aclaris' website. The webcast will be archived for at least 30 days. Aclaris focuses on developing novel drug candidates for patients with immuno-inflammatory diseases and boasts a multi-stage portfolio powered by a strong R&D engine, addressing significant treatment gaps in this area.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced preliminary topline results from its Phase 2a study evaluating zunsemetinib for treating moderate to severe hidradenitis suppurativa (HS). The study, involving 95 patients across 19 sites, did not meet its primary endpoint of reduced inflammatory nodule/abscess count compared to placebo. Secondary efficacy endpoints were also unmet. Although zunsemetinib's safety profile was consistent with prior studies, notable treatment-emergent adverse events included dizziness (16.7%) and diarrhea (12.5%). Aclaris remains optimistic about zunsemetinib's mechanism of action and is looking forward to upcoming data from its Phase 2b rheumatoid arthritis study.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported its financial results for Q4 and the full year of 2022, highlighting a net loss of $27.6 million for Q4, up from $22.8 million in Q4 2021. Total revenue rose to $7.8 million in Q4, driven by $6.7 million in licensing revenue. For the full year, Aclaris recorded a net loss of $86.9 million, an improvement from $90.9 million in 2021. Revenue increased to $29.8 million, mainly due to licensing agreements, including $17.6 million from Eli Lilly. The company has $229.8 million in cash and equivalents, expected to fund operations through 2025. Upcoming milestones include topline data from clinical trials for zunsemetinib in hidradenitis suppurativa in March 2023.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a biopharmaceutical company, will participate in a fireside chat during the Virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 9:20 AM ET. The event can be accessed via a webcast on the company’s website, where it will be archived for 30 days. Aclaris focuses on developing innovative drug candidates for immuno-inflammatory diseases, aiming to meet the needs of patients with limited treatment options. The company features a strong R&D pipeline exploring protein kinase regulation.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) provided a positive corporate outlook for 2023, highlighting key clinical milestones for their lead programs, zunsemetinib and ATI-1777. The company plans to release topline data for several trials, including rheumatoid arthritis and atopic dermatitis, in mid to late 2023. Aclaris is also progressing ATI-2138 for T cell-mediated diseases and ATI-2231 for oncology. An upcoming presentation at the J.P. Morgan Healthcare Conference on January 11 will further discuss the company’s developments. Aclaris aims to address unmet needs in immuno-inflammatory diseases.
